| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
|
Lancet
|
2010
|
18.36
|
|
2
|
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
|
N Engl J Med
|
2012
|
9.88
|
|
3
|
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.
|
Kidney Int
|
2010
|
9.25
|
|
4
|
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
|
Lancet
|
2015
|
7.99
|
|
5
|
Cystatin C versus creatinine in determining risk based on kidney function.
|
N Engl J Med
|
2013
|
7.98
|
|
6
|
Age and association of kidney measures with mortality and end-stage renal disease.
|
JAMA
|
2012
|
7.20
|
|
7
|
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.
|
JAMA
|
2012
|
6.26
|
|
8
|
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.
|
Kidney Int
|
2011
|
5.47
|
|
9
|
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.
|
Kidney Int
|
2011
|
5.25
|
|
10
|
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
|
Lancet
|
2012
|
4.87
|
|
11
|
Genetic loci influencing kidney function and chronic kidney disease.
|
Nat Genet
|
2010
|
3.75
|
|
12
|
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
|
Nephrol Dial Transplant
|
2006
|
2.50
|
|
13
|
Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort.
|
Kidney Int
|
2010
|
2.48
|
|
14
|
Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients.
|
Am J Kidney Dis
|
2011
|
2.38
|
|
15
|
Microalbuminuria and risk of venous thromboembolism.
|
JAMA
|
2009
|
2.35
|
|
16
|
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
|
Eur Heart J
|
2013
|
2.32
|
|
17
|
Comparison of different measures of urinary protein excretion for prediction of renal events.
|
J Am Soc Nephrol
|
2010
|
2.22
|
|
18
|
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.
|
J Am Coll Cardiol
|
2013
|
2.18
|
|
19
|
Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.
|
Am J Epidemiol
|
2008
|
2.09
|
|
20
|
Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study.
|
Hypertension
|
2013
|
2.03
|
|
21
|
Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population.
|
Atherosclerosis
|
2009
|
1.88
|
|
22
|
High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate.
|
Eur Heart J
|
2012
|
1.86
|
|
23
|
Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
|
Clin J Am Soc Nephrol
|
2012
|
1.78
|
|
24
|
Association of cognitive function with albuminuria and eGFR in the general population.
|
Clin J Am Soc Nephrol
|
2011
|
1.77
|
|
25
|
An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population.
|
Kidney Int Suppl
|
2004
|
1.71
|
|
26
|
Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients.
|
Transplantation
|
2009
|
1.69
|
|
27
|
Sodium excretion and risk of developing coronary heart disease.
|
Circulation
|
2014
|
1.67
|
|
28
|
Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
|
Nephrol Dial Transplant
|
2012
|
1.67
|
|
29
|
Fact or fiction of the epidemic of chronic kidney disease--let us not squabble about estimated GFR only, but also focus on albuminuria.
|
Nephrol Dial Transplant
|
2008
|
1.61
|
|
30
|
Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts.
|
Circulation
|
2012
|
1.59
|
|
31
|
Screening for chronic kidney disease: where does Europe go?
|
Clin J Am Soc Nephrol
|
2008
|
1.56
|
|
32
|
Urinary and plasma magnesium and risk of ischemic heart disease.
|
Am J Clin Nutr
|
2013
|
1.54
|
|
33
|
Electrocardiographic abnormalities and uremic cardiomyopathy.
|
Kidney Int
|
2005
|
1.51
|
|
34
|
Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients.
|
Hypertension
|
2006
|
1.49
|
|
35
|
Plasma renin and outcome in the community: data from PREVEND.
|
Eur Heart J
|
2012
|
1.47
|
|
36
|
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
|
Am J Kidney Dis
|
2011
|
1.39
|
|
37
|
Glomerular and tubular damage markers are elevated in patients with diabetes.
|
Diabetes Care
|
2011
|
1.39
|
|
38
|
Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events.
|
Br J Clin Pharmacol
|
2008
|
1.39
|
|
39
|
[Measurement of protein loss in the urine. A useful addition in cardiovascular disease risk assessment].
|
Ned Tijdschr Geneeskd
|
2009
|
1.39
|
|
40
|
Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects.
|
J Renin Angiotensin Aldosterone Syst
|
2007
|
1.37
|
|
41
|
Early renal abnormalities in autosomal dominant polycystic kidney disease.
|
Clin J Am Soc Nephrol
|
2010
|
1.32
|
|
42
|
Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function.
|
J Am Soc Nephrol
|
2004
|
1.30
|
|
43
|
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
|
Clin Ther
|
2006
|
1.28
|
|
44
|
Loci influencing blood pressure identified using a cardiovascular gene-centric array.
|
Hum Mol Genet
|
2013
|
1.27
|
|
45
|
One risk assessment tool for cardiovascular disease, type 2 diabetes, and chronic kidney disease.
|
Diabetes Care
|
2012
|
1.21
|
|
46
|
Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
|
Am J Physiol Renal Physiol
|
2011
|
1.17
|
|
47
|
Cohort profile: the chronic kidney disease prognosis consortium.
|
Int J Epidemiol
|
2012
|
1.16
|
|
48
|
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
|
Clin J Am Soc Nephrol
|
2010
|
1.16
|
|
49
|
Update on microalbuminuria as a biomarker in renal and cardiovascular disease.
|
Curr Opin Nephrol Hypertens
|
2006
|
1.15
|
|
50
|
Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
|
Am J Kidney Dis
|
2010
|
1.15
|
|
51
|
Urinary creatinine excretion reflecting muscle mass is a predictor of mortality and graft loss in renal transplant recipients.
|
Transplantation
|
2008
|
1.13
|
|
52
|
Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study.
|
Am J Kidney Dis
|
2012
|
1.13
|
|
53
|
Early detection of progressive chronic kidney disease: is it feasible?
|
J Am Soc Nephrol
|
2006
|
1.10
|
|
54
|
N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population.
|
Eur Heart J
|
2009
|
1.08
|
|
55
|
Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension.
|
Circulation
|
2012
|
1.08
|
|
56
|
Lead and CKD.
|
Nephrol Dial Transplant
|
2012
|
1.07
|
|
57
|
The association between atherosclerotic risk factors and renal function in the general population.
|
Kidney Int
|
2005
|
1.07
|
|
58
|
Accepting or declining dialysis: considerations taken into account by elderly patients with end-stage renal disease.
|
J Nephrol
|
2009
|
1.04
|
|
59
|
Blood pressure in early autosomal dominant polycystic kidney disease.
|
N Engl J Med
|
2015
|
1.04
|
|
60
|
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).
|
Am Heart J
|
2011
|
1.04
|
|
61
|
Reference data for the Ruff Figural Fluency Test stratified by age and educational level.
|
PLoS One
|
2011
|
1.02
|
|
62
|
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
|
Am J Kidney Dis
|
2012
|
1.01
|
|
63
|
Influence of age and measure of eGFR on the association between renal function and cardiovascular events.
|
Clin J Am Soc Nephrol
|
2010
|
1.00
|
|
64
|
Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31).
|
Diabetes Care
|
2013
|
0.99
|
|
65
|
The association of APOE genotype with cognitive function in persons aged 35 years or older.
|
PLoS One
|
2011
|
0.98
|
|
66
|
Inflammation reduces HDL protection against primary cardiac risk.
|
Eur J Clin Invest
|
2010
|
0.98
|
|
67
|
Socioeconomic measures and CKD in the United States and The Netherlands.
|
Clin J Am Soc Nephrol
|
2013
|
0.93
|
|
68
|
Diagnostic potential of circulating natriuretic peptides in chronic kidney disease.
|
Nephrol Dial Transplant
|
2005
|
0.92
|
|
69
|
Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease.
|
J Lipid Res
|
2010
|
0.92
|
|
70
|
Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients.
|
Nephrol Dial Transplant
|
2006
|
0.92
|
|
71
|
Age and cystatin C in healthy adults: a collaborative study.
|
Nephrol Dial Transplant
|
2009
|
0.92
|
|
72
|
Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?
|
J Nephrol
|
2007
|
0.91
|
|
73
|
Hypertension and low HDL cholesterol were associated with reduced kidney function across the age spectrum: a collaborative study.
|
Ann Epidemiol
|
2013
|
0.90
|
|
74
|
Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy.
|
Am J Hypertens
|
2005
|
0.90
|
|
75
|
A genome-wide association study of circulating galectin-3.
|
PLoS One
|
2012
|
0.89
|
|
76
|
Sex differences in new-onset heart failure.
|
Clin Res Cardiol
|
2014
|
0.89
|
|
77
|
Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study.
|
J Clin Endocrinol Metab
|
2013
|
0.88
|
|
78
|
Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease.
|
Ann Intern Med
|
2014
|
0.88
|
|
79
|
Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
|
Clin Ther
|
2010
|
0.88
|
|
80
|
Effect of frozen storage on urinary concentration of kidney damage markers.
|
Am J Kidney Dis
|
2011
|
0.88
|
|
81
|
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
|
Kidney Int
|
2013
|
0.87
|
|
82
|
External validation of the KORA S4/F4 prediction models for the risk of developing type 2 diabetes in older adults: the PREVEND study.
|
Eur J Epidemiol
|
2012
|
0.87
|
|
83
|
Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality.
|
J Am Heart Assoc
|
2012
|
0.87
|
|
84
|
Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes.
|
Diabetes Care
|
2012
|
0.87
|
|
85
|
Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts.
|
PLoS One
|
2012
|
0.86
|
|
86
|
Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-pro-endothelin-1.
|
Hypertension
|
2013
|
0.86
|
|
87
|
Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study.
|
J Clin Oncol
|
2013
|
0.86
|
|
88
|
Cardiovascular risk profile and cognitive function in young, middle-aged, and elderly subjects.
|
Stroke
|
2013
|
0.86
|
|
89
|
Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
|
Clin Chem
|
2011
|
0.85
|
|
90
|
High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes.
|
J Hypertens
|
2013
|
0.85
|
|
91
|
N-terminal pro-B-type natriuretic peptide and mortality in renal transplant recipients versus the general population.
|
Transplantation
|
2009
|
0.85
|
|
92
|
Metabolic syndrome: a fata morgana?
|
Nephrol Dial Transplant
|
2006
|
0.85
|
|
93
|
Glomerular and tubular damage markers in individuals with progressive albuminuria.
|
Clin J Am Soc Nephrol
|
2013
|
0.85
|
|
94
|
Urinary semaphorin 3A correlates with diabetic proteinuria and mediates diabetic nephropathy and associated inflammation in mice.
|
J Mol Med (Berl)
|
2014
|
0.85
|
|
95
|
Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
|
Am J Kidney Dis
|
2013
|
0.85
|
|
96
|
Fasting insulin modifies the relation between age and renal function.
|
Nephrol Dial Transplant
|
2007
|
0.84
|
|
97
|
Prevention of chronic kidney disease: the next step forward!
|
Nephrology (Carlton)
|
2006
|
0.84
|
|
98
|
Tolvaptan in autosomal dominant polycystic kidney disease.
|
N Engl J Med
|
2013
|
0.84
|
|
99
|
Fasting insulin is a stronger cardiovascular risk factor in women than in men.
|
Atherosclerosis
|
2008
|
0.84
|
|
100
|
Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risk?
|
Curr Hypertens Rep
|
2005
|
0.84
|
|
101
|
Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population.
|
Heart
|
2012
|
0.83
|
|
102
|
The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate.
|
Br J Clin Pharmacol
|
2007
|
0.83
|
|
103
|
Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC.
|
Kidney Int Suppl
|
2004
|
0.83
|
|
104
|
Isolated microalbuminuria indicates a poor medical prognosis.
|
Nephrol Dial Transplant
|
2013
|
0.83
|
|
105
|
Albuminuria in non-primary renal disease: risk marker rather than risk factor.
|
Nephrol Dial Transplant
|
2009
|
0.82
|
|
106
|
Netrin-1, a urinary proximal tubular injury marker, is elevated early in the time course of human diabetes.
|
J Nephrol
|
2014
|
0.82
|
|
107
|
Cystatin C versus creatinine for kidney function-based risk.
|
N Engl J Med
|
2013
|
0.82
|
|
108
|
Low incidence of nephropathy in surgical ICU patients receiving intravenous contrast: a retrospective analysis.
|
Intensive Care Med
|
2006
|
0.82
|
|
109
|
Cholesteryl Ester Transfer Protein (CETP) genotype and cognitive function in persons aged 35 years or older.
|
Neurobiol Aging
|
2012
|
0.81
|
|
110
|
Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making.
|
Pharmacoeconomics
|
2006
|
0.81
|
|
111
|
Determinants of insulin resistance in renal transplant recipients.
|
Transplantation
|
2007
|
0.81
|
|
112
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
Am J Nephrol
|
2015
|
0.81
|
|
113
|
Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant recipients.
|
Nephrol Dial Transplant
|
2005
|
0.81
|
|
114
|
Dialysis hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and meta-analysis.
|
Am J Nephrol
|
2014
|
0.81
|
|
115
|
Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study.
|
Thromb Haemost
|
2012
|
0.81
|
|
116
|
LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP.
|
Atherosclerosis
|
2010
|
0.81
|
|
117
|
Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis.
|
PLoS One
|
2012
|
0.81
|
|
118
|
Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study.
|
Br J Haematol
|
2012
|
0.80
|
|
119
|
Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
|
J Clin Lipidol
|
2012
|
0.80
|
|
120
|
Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein.
|
Metabolism
|
2012
|
0.80
|
|
121
|
Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
|
Expert Opin Investig Drugs
|
2015
|
0.80
|
|
122
|
Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome.
|
J Clin Endocrinol Metab
|
2010
|
0.79
|
|
123
|
Mediators of the association between low socioeconomic status and chronic kidney disease in the United States.
|
Am J Epidemiol
|
2015
|
0.79
|
|
124
|
Validation of insulin resistance indexes in a stable renal transplant population.
|
Diabetes Care
|
2005
|
0.79
|
|
125
|
The effect of screening for cardio-renal risk factors on drug use in the general population.
|
Br J Clin Pharmacol
|
2007
|
0.79
|
|
126
|
Focus on microalbuminuria to improve cardiac and renal protection.
|
Nephron Clin Pract
|
2009
|
0.79
|
|
127
|
Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study.
|
Br J Haematol
|
2012
|
0.79
|
|
128
|
Screening for early chronic kidney disease--what method fits best?
|
Nephrol Dial Transplant
|
2006
|
0.79
|
|
129
|
Albuminuria: is it time to screen the general population?
|
Adv Chronic Kidney Dis
|
2011
|
0.79
|
|
130
|
Differences between physicians in the likelihood of referral and acceptance of elderly patients for dialysis-influence of age and comorbidity.
|
Nephrol Dial Transplant
|
2007
|
0.78
|
|
131
|
Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes.
|
J Hypertens
|
2015
|
0.78
|
|
132
|
Screening techniques for detecting chronic kidney disease.
|
Curr Opin Nephrol Hypertens
|
2005
|
0.78
|
|
133
|
Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort.
|
Clin Chem Lab Med
|
2015
|
0.77
|
|
134
|
Predictors of progression in albuminuria in the general population: results from the PREVEND cohort.
|
PLoS One
|
2013
|
0.77
|
|
135
|
What to measure-albuminuria or total proteinuria?
|
Am J Kidney Dis
|
2011
|
0.77
|
|
136
|
Effects of potassium supplementation on markers of osmoregulation and volume regulation: results of a fully controlled dietary intervention study.
|
J Hypertens
|
2016
|
0.77
|
|
137
|
Determinants and prognostic significance of an intra-dialysis rise of cardiac troponin I measured by sensitive assay in hemodialysis patients.
|
Clin Res Cardiol
|
2013
|
0.77
|
|
138
|
Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
|
Diabetologia
|
2014
|
0.77
|
|
139
|
Is cystatin C the answer to detecting progression in CKD?
|
J Am Soc Nephrol
|
2010
|
0.77
|
|
140
|
Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system.
|
Kidney Int
|
2008
|
0.77
|
|
141
|
Moderator's view: Estimating glomerular filtration rate--the past, present and future.
|
Nephrol Dial Transplant
|
2013
|
0.77
|
|
142
|
Exploration of the difference in incidence of renal replacement therapy in elderly patients in Flanders and the Netherlands--a comparison of referral policy.
|
Nephrol Dial Transplant
|
2011
|
0.77
|
|
143
|
The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort.
|
J Am Heart Assoc
|
2014
|
0.76
|
|
144
|
Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events.
|
Nephrol Dial Transplant
|
2013
|
0.76
|
|
145
|
Exploration of the difference in incidence of renal replacement therapy between Flanders and the Netherlands--investigation of explanatory variables.
|
Nephrol Dial Transplant
|
2011
|
0.76
|
|
146
|
Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria.
|
Nephrol Dial Transplant
|
2007
|
0.75
|
|
147
|
Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
|
Am J Nephrol
|
2016
|
0.75
|
|
148
|
Correction: The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study.
|
PLoS Genet
|
2016
|
0.75
|
|
149
|
Vasopressin and microalbuminuria: is it vasopressin per se or is it salt intake?
|
Kidney Int
|
2010
|
0.75
|
|
150
|
Urinary biomarkers in autosomal dominant polycystic kidney disease: is there no prognostic value?
|
Kidney Int
|
2012
|
0.75
|
|
151
|
Plasma procalcitonin is an independent predictor of graft failure late after renal transplantation.
|
Transplantation
|
2009
|
0.75
|
|
152
|
Statin use and cognitive function: population-based observational study with long-term follow-up.
|
PLoS One
|
2015
|
0.75
|
|
153
|
Response to Lowered magnesium in hypertension.
|
Hypertension
|
2013
|
0.75
|
|
154
|
Cost-effectiveness of screening for proteinuria.
|
JAMA
|
2004
|
0.75
|
|
155
|
Albuminuria: what can we expect from the determination of nonimmunoreactive albumin?
|
Curr Hypertens Rep
|
2009
|
0.75
|
|
156
|
Corrigendum: Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk.
|
Nat Genet
|
2017
|
0.75
|
|
157
|
Quiz page. Xanthogranulomatous pyelonephritis.
|
Am J Kidney Dis
|
2003
|
0.75
|
|
158
|
The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
|
Am J Nephrol
|
2017
|
0.75
|
|
159
|
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
|
Am J Nephrol
|
2017
|
0.75
|
|
160
|
Genome-wide association studies identify genetic loci for low von Willebrand factor levels.
|
Eur J Hum Genet
|
2016
|
0.75
|
|
161
|
Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
|
Am J Nephrol
|
2015
|
0.75
|
|
162
|
Erratum.
|
Nephrol Dial Transplant
|
2017
|
0.75
|
|
163
|
[Autosomal dominant polycystic kidney disease: new insights and possible drugs].
|
Ned Tijdschr Geneeskd
|
2009
|
0.75
|